Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.52 |
| ▸ | THRB | P10828 | 12/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PCNA | P12004 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145813 | 0.88 | THRA (0.52) | THRATHRBKDM4EFFAR1HPGD | |
| SCHEMBL3145340 | 0.87 | THRA (0.55) | THRATHRBKDM4EFFAR1HPGD | |
| SCHEMBL5074393 | 0.82 | KDM4E (0.37) | THRATHRBKDM4EFFAR1HPGD | |
| SCHEMBL3127311 | 0.77 | THRA (0.45) | THRATHRB | |
| SCHEMBL3137560 | 0.76 | THRA (0.46) | THRATHRBKDM4EHPGDPOLB | |
| SCHEMBL3138058 | 0.76 | THRA (0.41) | THRATHRBKDM4EHPGD | |
| SCHEMBL3145925 | 0.76 | THRA (0.45) | THRATHRB | |
| SCHEMBL3140997 | 0.74 | THRA (0.55) | THRATHRBKDM4EFFAR1HPGD | |
| SCHEMBL5073565 | 0.74 | KDM4E (0.38) | KDM4EHPGDPOLB | |
| SCHEMBL3137511 | 0.73 | THRA (0.52) | THRATHRBMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | THRA 4/4885THRB 6/4885KDM4E 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.